Acalabrutinib Monotherapy vs Combination Therapy in Treatment-Naïve CLL
Study Snapshot
- Study: Retrospective real-world study
- Population: Patients with treatment-naïve chronic lymphocytic leukemia (CLL)
- Sample size: 81 patients (monotherapy: n=21; combination: n=60)
- Treatment: Acalabrutinib monotherapy vs acalabrutinib + obinutuzumab
- Focus: Efficacy and safety comparison as first-line treatment
Study Background
Researchers compared the efficacy and safety of acalabrutinib monotherapy and acalabrutinib plus obinutuzumab as first-line treatment for CLL. Baseline characteristics were similar between both groups.
Key Results
Adverse Events
- Grade ≥3 AEs: 56.7% (combination) vs 38.1% (monotherapy)
- Bleeding: 35.0% vs 23.8%
- Cardiac events: 23.3% vs 9.5%
- Infusion-related reactions: 10% (combination only)
- Dose modifications due to AEs: 60.0% vs 57.1%
Response Rates
- Complete response: 80.0% (combination) vs 19.0% (monotherapy)
- Partial response: 16.7% (combination) vs 61.9% (monotherapy)
Survival (median follow-up: 25 months)
- PFS: 88.3% (combination) vs 85.7% (monotherapy)
- OS: 95% (combination) vs 81% (monotherapy)
Clinical Takeaway
Both acalabrutinib monotherapy and combination therapy are effective first-line treatments for CLL. Acalabrutinib monotherapy may be a more viable option for patients at greater risk for toxicities.
Link to Abstract
Cancer Screening Adherence in Patients With CLL/SLL
Study Snapshot
- Study: Retrospective study
- Population: Patients aged 50–75 with CLL/SLL
- Data source: TriNetX Research Network
- Focus: Colorectal and breast cancer screening compliance rates
Study Background
The risk of second primary malignancy is increased in patients with CLL/small lymphocytic lymphoma (SLL). Researchers assessed the rate of screenings for colorectal and breast cancers among eligible patients with CLL/SLL.
Key Results
Breast Cancer Screening
- Women with CLL/SLL: 36,475
- Underwent screening mammography: 7,158 (~20% compliance)
- Breast malignancy risk: 7.8% (screened) vs 6.2% (unscreened)
- OS significantly improved in screened patients (p<0.0001)
Colorectal Cancer Screening
- Total patients: 92,728
- Underwent colonoscopy: 11,232 (~12% compliance)
- Colon cancer risk: 1.9% (screened) vs 1.3% (unscreened)
- OS significantly improved in screened patients (p<0.0001)
Clinical Takeaway
Adherence to cancer screenings among patients with CLL/SLL is suboptimal, highlighting the need for improved compliance with both breast and colorectal cancer screening in this population.
Link to Abstract
Survival Disparities in CLL/SLL: Academic vs Community Cancer Programs
Study Snapshot
- Study: Retrospective analysis
- Data source: US National Cancer Database (2004–2022)
- Sample size: 200,249 patients (ACP: n=102,545; CCP: n=97,704)
- Focus: Treatment patterns and survival outcomes by program type
Study Background
Researchers compared differences in treatment patterns and survival outcomes among patients with CLL/SLL treated at academic cancer programs (ACPs) versus community cancer programs (CCPs).
Key Results
Patient Demographics
- Black patients: 9.2% (ACP) vs 6.3% (CCP)
- Hispanic patients: 3.4% (ACP) vs 2.3% (CCP)
- Age <60 years: 23.1% (ACP) vs 18.6% (CCP)
- Age ≥75 years: 31.9% (ACP) vs 37.4% (CCP)
- Charlson-Deyo score ≥2: 8.5% (ACP) vs 7.9% (CCP); p=0.006
- Median travel distance: 10.2 miles (ACP) vs 7.5 miles (CCP); p<0.001
Treatment Patterns
- Watchful waiting: 37.6% (ACP) vs 33.0% (CCP)
- No treatment: 17.2% (ACP) vs 20.9% (CCP); p<0.001
- Systemic therapy: 19.4% (ACP) vs 19.3% (CCP)
- Median time to treatment was longer at ACPs (all p≤0.004)
Survival
- 2-year OS: 84.3% (ACP) vs 84.4% (CCP)
- 5-year OS: 69.1% (ACP) vs 68.3% (CCP)
- 10-year OS: 47.8% (ACP) vs 46.1% (CCP); p<0.001
- Treatment at ACP independently associated with improved OS (HR: 0.95; 95% CI: 0.93–0.97; p<0.001)
Clinical Takeaway
Treatment at an academic cancer program was independently associated with improved overall survival in patients with CLL/SLL, despite longer travel distances and time to treatment initiation.
Link to Abstract
POD36 as a Predictor of Poor Survival in CLL on Targeted Therapy
Study Snapshot
- Study: Retrospective analysis
- Population: Patients with CLL receiving first-line targeted therapy
- Sample size: 787 patients
- Focus: Prognostic impact of disease progression within 36 months (POD36)
Study Background
Progression within 24 months of chemoimmunotherapy is a known poor prognostic factor in CLL, but the prognostic impact of early progression on targeted therapy has been unclear. Researchers compared survival outcomes between patients who experienced progressive disease within 36 months of targeted therapy initiation (POD36) and those without early progression.
Key Results
- Median age at treatment initiation: 67 years; 67% male
- Of 519 patients with CLL-IPI data: 44% high-risk, 15% very high-risk
- At median follow-up of 50 months, 72 of 496 evaluable patients (15%) experienced POD36
- TP53 disruption associated with POD36 (OR: 2.9; 95% CI: 1.5–5.7; p=0.001)
- OS significantly shorter in POD36 vs non-POD36 patients (HR: 3.5; 95% CI: 2.1–6.0; p<0.0001)
- Estimated 4-year OS: 65% (POD36) vs 88% (non-POD36)
- Landmark analysis confirmed decreased OS in POD36 patients still alive at 3 years (HR: 3.5; 95% CI: 1.8–6.8; p=0.0002)
- Multivariable analysis: POD36 significantly associated with decreased OS (HR: 4.2; 95% CI: 2.1–8.4; p<0.0001)
Clinical Takeaway
Progression within 36 months of first-line targeted therapy is an independent predictor of poor overall survival in patients with CLL, supporting POD36 as a clinically meaningful prognostic benchmark in this setting.
Link to Abstract
Predictors of Richter Transformation in CLL
Study Snapshot
- Study: Real-world retrospective study
- Population: Patients with CLL evaluated for possible Richter transformation via PET-CT and biopsy
- Sample size: 249 patients
- Focus: Predictors of Richter transformation and outcomes in nodal progression CLL
Study Background
This study aimed to identify real-world predictors of Richter transformation (RT) in CLL. Eligible patients underwent PET-CT and biopsy within 3 months to evaluate possible RT. Of 249 patients, 70 were classified as transformed (NP-T) and 179 had NP-CLL, 12 of whom were diagnosed with RT on repeat biopsy.
Key Results
Predictors of Transformation
- Progression <1.54 years from targeted therapy initiation to PET: OR 4.33 (95% CI: 1.05–17.84; p=0.0422)
- Number of prior therapies: OR 1.32 per line (95% CI: 1.07–1.64; p=0.0094)
- Maximum standardized uptake value: OR 2.65 per 5-unit increase (95% CI: 1.95–3.59; p<0.0001)
Protective Factors
- Treatment-naïve status: OR 0.37 (95% CI: 0.21–0.67; p=0.0010)
- Trisomy 12: OR 0.45 (95% CI: 0.21–0.93; p=0.0400)
Survival
- Median OS: 1.75 years (NP-T) vs 7.71 years (NP-CLL); p<0.0001
- NP-CLL vs treated CLL cohort 5-year OS: 86.0% vs 94.9%
- NP-CLL vs treated CLL cohort 10-year OS: 54.7% vs 82.7%; p<0.0001
Clinical Takeaway
Early progression on targeted therapy, higher prior treatment burden, and elevated PET uptake were identified as independent predictors of Richter transformation, while treatment-naïve status and trisomy 12 were protective. NP-CLL represents a distinct high-risk subgroup with significantly worse survival compared to the broader CLL population.